Wolfgang Miesbach: Cognitive Impairment in aPL-Positive Patients
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Cognitive impairment in aPL-positive patients.
An important presentation by Gustavo Balbi and colleagues on the real-world recognition and management of cognitive impairment in patients with antiphospholipid antibodies (aPL).
Clinicians most frequently associated aPL with depression, anxiety, impaired attention, slower processing speed, and memory or executive dysfunction.
Yet routine cognitive screening remains uncommon – particularly in patients without stroke and TIA or overt symptoms.
Stronger collaboration between APS specialists, cognitive neurologists, and neuropsychologists is urgently needed to improve recognition, assessment, and care.”
Other posts featuring Wolfgang Miesbach on Hemostasis Today.
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin
-
Aug 10, 2026, 15:47Edward Lee Carter: 61% of Patients on Reduced-Dose Apixaban Did Not Meet Label Criteria
-
Aug 10, 2026, 15:45Vrushali Lad: What Living With DVT Taught Me About Lifestyle and Movement
-
Aug 10, 2026, 15:39Iftikhar Khan: What Is the Optimal Antithrombotic Strategy After Left Atrial Appendage Closure?
-
Aug 10, 2026, 15:36Anas Hamad: Medication Adherence and Treatment Persistence Following the Switch From VKAs to DOACs
-
Aug 10, 2026, 15:11Shazmah Shaikh: How Does a Thrombus Actually Form?
-
Aug 10, 2026, 15:01William Wallace: Is Your Cholesterol Test Missing Your Biggest Inherited Risk?